You are here: Industry Insights > HBM

News List

Numab Therapeutics secures $110m in Series C funding round pharmaceutical-technology
May 24, 2021
Numab Therapeutics has raised approximately $110m (CHF100m) through Series C funding to expedite the clinical development of its multi-specific antibody pipeline in oncology and inflammation.
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting prnasia
April 13, 2021
Harbour BioMed, a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis prnasia
January 28, 2021
Harbour BioMed (HBM), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with ...
AbbVie and partners to develop monoclonal antibody against Covid-19 pharmaceutical-technology
June 09, 2020
AbbVie has partnered with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapeutic for the prevention and treatment of Covid-19.
Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19 pharmaceutical-business-review
March 12, 2020
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.